Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy…
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft– – The observed synergy emphasizes VCN-01's potential in diverse chemotherapy combinations for improved efficacy in the treatment of pancreatic cancer– ROCKVILLE, Md., April22, 2024(GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer...
Nasdaq GlobeNewswire
22/04/2024
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene…
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April22, 2024(GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene...
Nasdaq GlobeNewswire
22/04/2024
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for…
With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2]. ...
PR Newswire
22/04/2024
Report of transactions of shares and related securities of Bavarian Nordic by…
COPENHAGEN, Denmark, April 22, 2024– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.The transactions concern the vesting of restricted stock units (RSUs) awarded to members of the Board of Directors of Bavarian Nordic A/S as part of their remuneration for 2021, and in accordance with the decision by...
Nasdaq GlobeNewswire
22/04/2024
LABCONNECT ACQUIRES SCIENTIFIC CONSULTANCY A4P
A4P is headquartered in Discovery Park, Sandwich, Kent, UK, with a wholly-owned subsidiary in Appenzell, Switzerland. With core expertise in regulated bioanalysis and genomics, biomarker strategy, personalized healthcare, biosample operations and bespoke logistics solutions, A4P serves a wide variety of clients across a broad range of therapeutic areas. A4P is headquartered in Discovery Park, Sandwich,Kent, UK, with a wholly-owned subsidiary in Appenzell,Switzerland. With core expertise...
PR Newswire
22/04/2024
Allergy Diagnostics Market Worth $9.8 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232871701 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232871701 Browse in-depth TOC on "Allergy Diagnostics Market" 248 - Tables57 - Figures 307 - Pages Allergy Diagnostics Market Scope: The consumables segment is expected to account for the largest share in 2023. The Allergy Diagnostics market, by product & service, has...
PR Newswire
22/04/2024
Immunovia announces updated financial calendar
For more information, please contact: For more information, please contact: Karin Almqvist Liwendahl Chief Financial
[email protected]
+46 709 11 56 08 Immunovia in brief Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a...
PR Newswire
22/04/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 22 April 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the...
Nasdaq GlobeNewswire
22/04/2024
Zeus Names Chief Technology Officer
"We are making significant investments in research and development, and it's exciting to have one of the industry's top innovators lead us into the future," said Zeus' CEO, Paddy O'Brien. "Suresh has a wealth of experience and expertise across med device design, emerging technologies, and developing next-gen catheter solutions. I'm confident his leadership over R&D will further strengthen our commitment to innovation and excellence and reinforce our value as a strategic…
PR Newswire
22/04/2024
Oculis Announces Closing of Registered Direct Offering and Commencement of…
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares toIcelandic institutional andexistinginvestors Becomes second company dual-listed on NASDAQ U.S. and NASDAQ Iceland Main Market, trading under the symbol “OCS” beginning April 23, 2024 Oculis will ring the Nasdaq Iceland opening bell on April 23, 2024, at 9:30 GMT Phase 2b RELIEF trial of OCS-02 (Licaminlimab) in Dry Eye Disease (DED) remains on track to readout in Q2...
Nasdaq GlobeNewswire
22/04/2024
Curaleaf Completes Acquisition of Northern Green Canada
Integrating NGC's international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland. Integrating NGC's international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions inGermany, theUnited KingdomandPoland. "We are...
PR Newswire
22/04/2024
Waters Accelerates the Development of Gene-based Therapeutics with New…
"The pipeline of nucleic acid therapeutics continues to grow at a double-digit paceii as developers strive to submit new investigational drug filings and complete their first in-human trials. The new Waters GTxResolve Premier SEC Columns supports the growing demand for mRNA, lipid nanoparticle, and viral vector-based therapies with columns that are more robust and provide higher efficiency," said Erin Chambers, Vice President, Consumables and Lab Automation, Waters Corporation…
PR Newswire
22/04/2024
Innovative Aspiration Thrombectomy System by Expanse ICE Receives FDA Clearance…
Eitan Konstantino, PhD, a serial entrepreneur in the vascular device field, is the driving force behind Expanse ICE. "We've engineered the ICE catheter system to harness the aspiration power typical of a large bore catheter, but within the slender profile of a much smaller device," Dr. Konstantino said. Eitan Konstantino, PhD, a serial entrepreneur in the vascular device field, is the driving force behind Expanse ICE. "We've engineered the ICE catheter system to harness the…
PR Newswire
22/04/2024
Landmark New Publication: the Forgotten Biochemistry 101 of COVID-19
The glycan monomer sialic acid, ubiquitous on eukaryotic cell surfaces, serves as the initial attachment point to host cells for the COVID–19 virus—SARS–CoV–2—as well as for other coronaviruses. The virus can then slide over to ACE2 for cell entry. SARS–CoV–2 spike protein attaches particularly tightly to the dense sialic acid coatings on the trillions of red blood cells (RBCs), platelets and endothelial cells in the human adult. These interlaced attachments trigger the RBC aggregation…
PR Newswire
22/04/2024
U.S. Institute of Peace Opens Nominations for 2024 Women Building Peace Award
The nomination period will run until June 10, 2024. USIP invites organizations and people across the globe to take part in identifying and honoring exceptional women who have dedicated their lives to building peace. The awardee will be recognized at a ceremony in Washington, DC, and will receive a cash prize. The nomination period will run untilJune 10, 2024. USIP invites organizations and people across the globe to take part in identifying and honoring exceptional women who have dedicated...
PR Newswire
22/04/2024
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple…
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-upAll Patients Have Either Stabilized or Improved on Nasal Foralumab Treatment and No Patients Declined in Key Clinical MeasuresNEW YORK, April22, 2024(GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug...
Nasdaq GlobeNewswire
22/04/2024
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in…
BOSTON and LONDON, April22, 2024(GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc(Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administered,...
Nasdaq GlobeNewswire
22/04/2024
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on…
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via telephone, please register...
Nasdaq GlobeNewswire
22/04/2024
Leo Cancer Care Teams up With World-Leading Carbon Ion Centre
A groundbreaking deal has been agreed with CNAO (National Center for Oncological Hadrontherapy) in Pavia, Italy. Marie® an upright patient positioning system combined with a vertical CT scanner, which will be placed in front of an existing fixed radiation beam with patients rotated slowly and smoothly to different beam angles as treatment is administered. A groundbreaking deal has been agreed with CNAO (National Center for Oncological Hadrontherapy) in Pavia,Italy. Marie® an upright patient...
PR Newswire
22/04/2024
Progesterone Therapy in Demand for Personalized Medicine: Market to Reach US$4.8…
Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19526 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19526 The progesterone market thrives because of the rising cases of breast cancer, AIDS, and amenorrhea and the adoption of progesterone in medicating the issues. Several researchers infer that progesterone and...
PR Newswire
22/04/2024
Super Generics Market Size Will Reach USD 128.62 Billion to 2031 - Revealed…
Download Free Report Sample Pages @https://www.insightaceanalytic.com/request-sample/2437 Download Free Report Sample Pages @https://www.insightaceanalytic.com/request-sample/2437 The Super Generics market encompasses an advanced category of generic drugs designed to offer additional benefits beyond traditional generics, such as enhanced efficacy, safety, or delivery mechanisms. This segment has been steadily growing, driven by factors including patent expirations of blockbuster drugs,...
PR Newswire
22/04/2024
Prescient Healthcare Group Announces the Appointment of Two New Members to Its…
Debbie Allman leads our global Commercial practice, focusing in particular on driving our growth in the US further. She is an accomplished commercial strategist with a broad range of experience in pharmaceutical commercialization and marketing. She started her career at AstraZeneca, holding numerous global and national (UK, Italy) marketing and sales roles over a 15-year period; in 2010, she began her consulting career by co-founding Strategic North, an insight-led brand strategy consultancy…
PR Newswire
22/04/2024
AIRS Medical Accelerates Global Expansion with MRI AI Solution SwiftMR™ Supply…
According to AIRS Medical, "RNZ proceeded to sign the final contract with high satisfaction after experiencing firsthand the improvement in image quality and increased productivity due to reduced scan times of over 10-year-old MRI scanner during the demo period." In particular, the company explained that the versatility of SwiftMR™, which can be used on various types of MRI scanner models as a standalone solution, played a significant role in securing the contract. According to AIRS…
PR Newswire
22/04/2024
Nexstim Receives NBS 6 System Order from Clinic in Florida, US
Press release, Helsinki, 22 April 2024 at 11 AM (EEST) Nexstim Receives NBS 6 System Order from Clinic in Florida, US Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a new clinic customer located in Florida, Unites States.Launched in 2023 in the United States and Europe, the NBS 6 is a new Nexstim product generation that brings the usability of the Nexstim system to a new level. The NBS 6 is currently FDA-approved for the...
Nasdaq GlobeNewswire
22/04/2024
Altri Comunicati